The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials

BACKGROUND: Thymosin α1 (Tα1) as immunomodulatory treatment is supposed to be beneficial for the sepsis patients by regulating T cell subsets and inflammatory mediators. However, limited by the small sample size and the poor study design, the persuasive power of the single clinical studies is weak....

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Fang, Wang, Hong-Mei, Wang, Tiansheng, Zhang, Ya-Mei, Zhu, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5025565/
https://www.ncbi.nlm.nih.gov/pubmed/27633969
http://dx.doi.org/10.1186/s12879-016-1823-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5025565/
https://www.ncbi.nlm.nih.gov/pubmed/27633969
http://dx.doi.org/10.1186/s12879-016-1823-5

Ejemplares similares